Holen Sie sich die Stockscreener-App
141.65
2.51%
-3.65
Handel nachbörslich:
141.90
0.25
+0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$145.30
Offen:
$145.3
24-Stunden-Volumen:
1.90M
Relative Volume:
1.06
Marktkapitalisierung:
$21.64B
Einnahmen:
$4.28B
Nettoeinkommen (Verlust:
$1.26B
KGV:
17.94
EPS:
7.8957
Netto-Cashflow:
$943.00M
1W Leistung:
+0.41%
1M Leistung:
+7.67%
6M Leistung:
+46.09%
1J Leistung:
+3.12%
1-Tages-Spanne:
$141.37
$145.42
1-Wochen-Bereich:
$140.19
$151.00
52-Wochen-Spanne:
$68.70
$151.34
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Vergleichen Sie ILMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
141.65 | 22.20B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
Oncology Research Solutions - Illumina
Illumina partners with pharma giants to map disease biology at unprecedented scale - Mugglehead Magazine
2026: A turning point for precision health - Illumina
Illumina's new connected multiomics platform set to boost its stock - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 54,987 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina reports 5% revenue growth in Q4 2025, flat for full year - Investing.com Nigeria
Illumina launches billion cell atlas to boost AI-driven drug discovery - Investing.com Nigeria
Illumina Launches Billion Cell Atlas to Accelerate AI-Driven Drug Development - filmogaz.com
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery - The Malaysian Reserve
Illumina CEO Sees Big Growth Opportunity in China - marketscreener.com
Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com
JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery - Pharmaceutical Technology
Illumina Produces Midteens Earnings Growth in 2025, Distancing Itself From the Grail Debacle - morningstar.com
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - GlobeNewswire
Illumina (NASDAQ:ILMN) Updates Q4 2025 Earnings Guidance - MarketBeat
Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset - marketscreener.com
Illumina Billion Cell Atlas to accelerate AI, drug discovery - BioWorld MedTech
Illumina Introduces Illumina Billion Cell Atlas To Accelerate AI Drug Discovery - Nasdaq
Illumina unveils dataset to speed up AI-powered drug discovery - Reuters
Illumina introduces billion cell atlas to accelerate AI and drug discovery - marketscreener.com
Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery - marketscreener.com
Illumina Preliminary Q4, Annual Results Beat Analysts' View - Nasdaq
Illumina Reports Preliminary Fiscal Q4 Non-GAAP Earnings, Revenue - marketscreener.com
(ILMN) Illumina Expects 2025 Revenue About $4.34B, vs. FactSet Est of $4.28B - marketscreener.com
Illumina reports preliminary Q4 revenue of $1.15B - MSN
Illumina Announces Preliminary Unaudited Financial Results for Q4 and Fiscal Year 2025 - TradingView — Track All Markets
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Illumina launches massive cell atlas to fast-track drug discovery - statnews.com
Assessing Illumina (ILMN) Valuation After New Multiomics Platform And Chief Medical Officer Appointment - Yahoo Finance
DNA Methylation Sequencing Market Set to Revolutionize - openPR.com
Illumina and PREMIA partner to expand clinical access to CGP in Asia - ANTARA News
Dr Eric Green named Illumina Chief Medical Officer - Medical Buyer
Illumina, Inc. (ILMN): A Closer Look At Its Growth Potential Amidst Analyst Ratings - DirectorsTalk Interviews
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 - WV News
Illumina names former NIH genomics director as chief medical officer - MedTech Dive
Illumina's New Connected Multiomics Platform Set to Boost Its Stock - The Globe and Mail
How Is The Market Feeling About Illumina Inc? - Benzinga
Hardman Johnston Global Advisors LLC Has $14.95 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
SG Americas Securities LLC Buys 53,795 Shares of Illumina, Inc. $ILMN - MarketBeat
Cerity Partners LLC Increases Stock Position in Illumina, Inc. $ILMN - MarketBeat
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Illumina Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Illumina names former NIH official as medical chief; commercial chief joins Quanterix - Seeking Alpha
Former NIH genomics director Eric Green to join Illumina as CMO - statnews.com
Precision Trading with Illumina Inc. (ILMN) Risk Zones - Stock Traders Daily
Will Illumina Inc. stock split again soon2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - ulpravda.ru
Can Illumina Inc. stock sustain revenue growthQuarterly Profit Review & Long-Term Safe Return Strategies - ulpravda.ru
Illumina Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):